(Q34787778)

4 August 2017

1 reference

title

What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates (English)

1 reference

4 August 2017

1 reference

David Y Graham

1

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Digestive Diseases and Sciences

4 August 2017

published in

1 reference

4 August 2017

volume

47

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

1665-1678

1 reference

Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate)

4 August 2017

cites work

1 reference

12 December 2020

Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa

1 reference

12 December 2020

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

12 December 2020

Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis

1 reference

12 December 2020

Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis

1 reference

12 December 2020

Response to alendronate in osteoporosis after previous treatment with etidronate

1 reference

12 December 2020

Study subjects and ordinary patients

1 reference

12 December 2020

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

1 reference

12 December 2020

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

12 December 2020

New bisphosphonates in the treatment of bone diseases

1 reference

12 December 2020

Risedronate: a clinical review

1 reference

12 December 2020

Effects of alendronate on gastric and duodenal mucosa

1 reference

12 December 2020

Design of the Fracture Intervention Trial

1 reference

12 December 2020

Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis.

1 reference

12 December 2020

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

12 December 2020

A gastroscopic and pharmacological study of the disintegration time and absorption of pivampicillin capsules and tablets

1 reference

12 December 2020

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

12 December 2020

Alendronate and naproxen are synergistic for development of gastric ulcers

1 reference

12 December 2020

Alendronate-associated esophagitis: endoscopic and pathologic features

1 reference

12 December 2020

Multiple ulcerative esophagitis caused by alendronate

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

A new probable increasing cause of esophageal ulceration: alendronate

1 reference

12 December 2020

[Alendronate-induced esophagitis. A report of 2 cases]

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

12 December 2020

Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy

1 reference

12 December 2020

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

1 reference

12 December 2020

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)

1 reference

12 December 2020

Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

The clinical tolerability profile of alendronate

1 reference

12 December 2020

Gastroscopic localization of a microencapsulated KCl preparation in the human stomach

1 reference

12 December 2020

Impaired oesophageal transit of capsule versus tablet formulations in the elderly

1 reference

12 December 2020

Pill-induced esophagitis caused by oral rifampin

1 reference

12 December 2020

Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.

1 reference

12 December 2020

Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin

1 reference

12 December 2020

1 reference

12 December 2020

Esophageal stricture associated with alendronate therapy

1 reference

12 December 2020

Esophageal irritation due to alendronate sodium tablets: possible mechanisms

1 reference

12 December 2020

Upper gastrointestinal adverse events and cyclical etidronate.

1 reference

12 December 2020

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

1 reference

12 December 2020

Gastroscopic and pharmacokinetic evaluation of a new pivmecillinam tablet

1 reference

12 December 2020

Tolerability of risedronate in postmenopausal women intolerant of alendronate

1 reference

12 December 2020

Nonclinical model for assessing gastric effects of bisphosphonates

1 reference

12 December 2020

Clodronate decreases the frequency of skeletal metastases in women with breast cancer

1 reference

12 December 2020

Alendronate induces gastric injury and delays ulcer healing in rodents

1 reference

12 December 2020

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

12 December 2020

A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.

1 reference

12 December 2020

Esophageal ulceration due to alendronate

1 reference

12 December 2020

Pamidronate: An unrecognized problem in gastrointestinal tolerability

1 reference

12 December 2020

Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety

1 reference

12 December 2020

1 reference

12 December 2020

Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate

1 reference

12 December 2020

The pharmacology of bisphosphonates and new insights into their mechanisms of action

1 reference

12 December 2020

Studies of the oral bioavailability of alendronate.

1 reference

12 December 2020

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

12 December 2020

Treatment of osteoporosis with bisphosphonates

1 reference

12 December 2020

Benign greater curve gastric ulcer: the "sump-ulcer"

1 reference

12 December 2020

Esophagitis and alendronate

1 reference

12 December 2020

Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH

1 reference

12 December 2020

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

1 reference

12 December 2020

Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women

1 reference

12 December 2020

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

12 December 2020

Upper gastrointestinal toxicity of alendronate

1 reference

12 December 2020

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

12 December 2020

Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate

1 reference

12 December 2020

Alendronate-induced ulcerative esophagitis

1 reference

12 December 2020

Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.

1 reference

12 December 2020

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study

1 reference

12 December 2020

Oesophageal stricture associated with alendronic acid

1 reference

12 December 2020

The effect of formulation on oesophageal transit

1 reference

12 December 2020

The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water

1 reference

12 December 2020

From the Food and Drug Administration

1 reference

12 December 2020

Comparative study of potential for bisphosphonates to damage gastric mucosa of rats

1 reference

12 December 2020

Alendronate-associated esophageal injury: pathologic and endoscopic features

1 reference

12 December 2020

Esophagitis dissecans superficialis and alendronate: case report

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Alendronate gastric ulcers

1 reference

12 December 2020

What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations

1 reference

12 December 2020

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

12 December 2020

The pathophysiology of gastro-oesophageal reflux disease: an overview

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

Incidence of gastrointestinal side effects due to alendronate is high in clinical practice

1 reference

12 December 2020

A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract

1 reference

12 December 2020

Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms

1 reference

12 December 2020

Alendronate in the treatment of osteoporosis: a review of the clinical trials

1 reference

12 December 2020

Improper alendronate administration and a case of pill esophagitis

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1016495221567

1 reference

Dimensions Publication ID

4 August 2017

1048501896

0 references

1 reference